GURUFOCUS.COM » STOCK LIST » USA » NAS » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Valuation Rank
Switch to:

Horizon Therapeutics (NAS:HZNP) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Horizon Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (NAS:HZNP) Business Description

Horizon Therapeutics logo
Traded in Other Exchanges
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Karin Rosen officer: EVP, R&D & CSO C/O HORIZON THERAPEUTICS, INC., CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Daniel A. Camardo officer: EVP and President, U.S. ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jeff Kent officer: See remarks C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4
Shao-lee Lin officer: EVP, Head of R&D and CSO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Irina Konstantinovsky officer: EVP, Chief Human Resources Off C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4
Eric Mosbrooker officer: SVP, Orphan Business Unit C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
James Samuel Shannon director 28903 NORTH AVENUE PAINE, VALENCIA CA 91355